HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

PU, Dugel; A, Koh; Y, Ogura; GJ, Jaffe; U, Schmidt-Erfurth; DM, Brown; AV, Gomes; J, Warburton; A, Weichselberger; FG, Holz

doi:10.1016/j.ophtha.2019.04.017

Public

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.

Shared by NobleBlocks on Apr 12, 2019 • 12:00 AM UTC

Authors:

Dugel PU

Koh A

Ogura Y

Abstract

<h4>Purpose</h4>Two similarly designed phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (nAMD).<h4>Design</h4>Double-masked, multicenter...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!